Krick Erika Lauren, Kiupel Matti, Durham Amy C, Thaiwong Tuddow, Brown Dorothy C, Sorenmo Karin U
From the School of Veterinary Medicine (E.L.K.), Department of Pathobiology (A.C.D.), and Department of Clinical Studies (D.C.B., K.U.S.), Veterinary Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, Pennsylvania; and Department of Pathobiology and Diagnostic Investigations, Diagnostic Center for Population and Animal Health (M.K.), and the Comparative Medicine and Integrative Biology Program (T.T.), Michigan State University, East Lansing, Michigan.
J Am Anim Hosp Assoc. 2017 Sep/Oct;53(5):258-264. doi: 10.5326/JAAHA-MS-6265. Epub 2017 Aug 9.
Previous studies have evaluated cellular proliferation indices, KIT expression, and c-kit mutations to predict the clinical behavior of canine mast cell tumors (MCTs). The study purpose was to retrospectively compare mitotic index, argyrophilic nucleolar organizer regions (AgNORs)/nucleus, Ki-67 index, KIT labeling pattern, and internal tandem duplication mutations in c-KIT between stage I and stage II grade II MCTs. Medical records and tumor biopsy samples from dogs with Grade II MCTs with cytological or histopathological regional lymph node evaluation were included. Signalment, tumor location and stage, and presence of a recurrent versus de novo tumor were recorded. Mitotic index, AgNORs/nucleus, Ki-67, KIT staining pattern, and internal tandem duplication mutations in exon 11 of c-KIT were evaluated. Sixty-six tumors (51 stage I; 15 stage II) were included. Only AgNORs/nucleus and recurrent tumors were significantly associated with stage (odds ratio 2.8, 95% confidence interval [CI] 1.0-8.0, P = .049; odds ratio 8.8, 95% CI 1.1-69.5; P = .039). Receiver-operator characteristic analysis showed that the sensitivity and specificity of AgNORs/cell ≥ 1.87 were 93.3% and 27.4%, respectively, (area under the curve: 0.65) for predicting stage. Recurrent tumors and higher AgNORs/nucleus are associated with stage II grade II MCTs; however, an AgNOR cutoff value that reliably predicts lymph node metastasis was not determined.
既往研究评估了细胞增殖指数、KIT表达及c-kit突变,以预测犬肥大细胞瘤(MCT)的临床行为。本研究目的是回顾性比较I期和II期II级MCT之间的有丝分裂指数、嗜银核仁组织区(AgNORs)/细胞核、Ki-67指数、KIT标记模式及c-KIT中的内部串联重复突变。纳入了患有II级MCT且经细胞学或组织病理学评估区域淋巴结的犬的病历及肿瘤活检样本。记录了信号、肿瘤位置和分期,以及复发性肿瘤与原发性肿瘤的情况。评估了有丝分裂指数、AgNORs/细胞核、Ki-67、KIT染色模式及c-KIT第11外显子中的内部串联重复突变。共纳入66个肿瘤(51个I期;15个II期)。仅AgNORs/细胞核及复发性肿瘤与分期显著相关(优势比2.8,95%置信区间[CI]1.0 - 8.0,P = 0.049;优势比8.8,95%CI 1.1 - 69.5;P = 0.039)。受试者工作特征分析显示,AgNORs/细胞≥1.87预测分期的敏感性和特异性分别为93.3%和27.4%(曲线下面积:0.65)。复发性肿瘤及较高的AgNORs/细胞核与II期II级MCT相关;然而,未确定能可靠预测淋巴结转移的AgNOR临界值。